Pionyr Immunotherapeutics is a clinical stage company that is developing cancer immunotherapies that target the tumor microenvironment to improve the antitumor immunity of the human body. Its approach, Myeloid Tuning™, has been designed to improve the immune system’s anti-tumor response by altering the myeloid infiltrate of the tumor microenvironment with high specificity and for specific purposes.
Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.
The Myeloid TuningTM technology of Pionyr builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells improves the ability of the body to combat cancer.